Introduction
There is now compelling evidence that latent Epstein-Barr virus (EBV) infection is controlled by a population of virus-specific (largely CD8+) cytotoxic T lymphocytes (CTL). These CTLs recognize epitopes frequently derived from EBV nuclear antigens (EBNA) 2, 3, 4 and 6 1, 2 . Although the mechanisms involved in controlling intermittent virus reactivation from latency have not yet been completely defined, it is clear that the interaction between specific CTL and their targets form a key element in preventing unchecked viral proliferation.
EBV-associated malignancies can arise in both immunosuppressed and immunocompetent individuals. These malignancies are of variable cellular origin and while some involve specific genetic lesions, all involve the expression of either some or all of the EBV latent proteins (reviewed in 1 ) . In developed countries EBV may be implicated in the pathogenesis of 30-50% of cases of . Recent data describes a specific HLA class I association with EBV-positive HL, suggesting that deficient antigenic presentation of LMP1/2
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Furthermore, HRS cells have evolved multiple strategies to evade the potent EBV-specific CTL response and these have been proposed to be linked to the cell-mediated immune deficiency that is present in the early phase of the disease.
Although the majority of patients with HL can be cured with currently available therapies, up to 30% of patients with advanced HL will progress or relapse 11 . New, more intensive chemotherapy regimens have significantly improved outcome 12 , however, less than half of relapsed and refractory patients will respond to conventional salvage strategies. These data have raised the possibility of combining immunotherapy with chemo/radiotherapy particularly in patients with relapsed/refractory EBV-positive HL. Indeed, a number of attempts have been made to expand EBV-specific T-cell immunity in vitro in the absence of an immunosuppressive environment, and to transfer the resulting expanded T-cells to treat patients with HL 13, 14 . However, an objective analysis of disease outcome highlights the need to explore alternate strategies to break tumor evasion mechanisms that preclude the development of a robust anti-tumor response. To enable further development of these strategies, it is important to understand the mechanism(s) by which the existing immune response to EBVencoded antigens fails to block the outgrowth of malignant cells. Previous studies on HL patients have indicated that EBV-specific T-cells can be detected in the peripheral circulation that recognize EBV-specific antigens which are expressed in HRS cells, yet this rarely corresponds with effective tumor eradication 15, 16 . Recent studies on human malignancies have suggested that the lack of an effective anti-tumor response may be due to activation of unique subsets of CD4+ Treg cells which specifically inhibit antigen-specific CD8+ T- 
Materials and Methods

Study Participants
A total of 94 newly diagnosed (ND), relapsed (RL) and remission (≥ 2 years from diagnosis) patients with histologically confirmed HL were included in this study. Table 1 provides details of the patient characteristics. One patient withdrew prior to providing samples. Data regarding age, gender, date of diagnosis and histology were collected in all patients. Mean age of the total group was 32 years (range 5-76 years) and 38% were female. In newlydiagnosed and relapsed patients, additional prognostic information was obtained to enable the prognostic score to be calculated 23 . To serve as controls, ELISPOT analysis was performed on blood from 29 healthy subjects (12 female: 17 male, mean age 43 years, range 23-63). There was no significant difference in gender mix between the four groups, however, both RL patients and healthy subjects were significantly older than ND patients (p=0.0497 and p=0.0006 respectively) and remission patients (p=0.0113 and p<0.0001 respectively). This study conformed to the tenets of the Declaration of Helsinki and informed consent was provided as per each participating sites research ethics process. This study was formally approved by the Human Ethics committees of QIMR, PeterMac Cancer Institute and PA Hospital.
Tissue Staining
All assays were carried out on sections of routinely fixed, paraffinembedded material. LMP1 and EBER assays were performed as per published guidelines 7 . The distribution of HRS cells was assessed by a morphologist on matching haematoxylin and eosin slides prior to interpreting the LMP1 and EBER staining. Following antigen retrieval with trypsin, the anti-LMP IgG1 or isotype control (Dako, CA, USA) was used to detect the presence of LMP1. 
Blood Samples
In ND and RL cases, 30ml of EDTA blood was taken at diagnosis (prior to initiation of therapy), and then at six monthly intervals for 1 year. With healthy subjects and remission cases, one 30ml blood sample was taken, and in the latter group the time interval from sample to diagnosis recorded. PBMC were prepared by gradient centrifugation (Ficoll-Paque; Amersham Biosciences, Sweden). PBMC were stored by controlled rate freezing in liquid nitrogen, and plasma samples were stored at -70°C until further processing.
Synthetic peptides.
Twenty nine EBV-epitope synthetic peptides presented by a wide range of HLA class I alleles covering >90% of Caucasians were used in this study [35] [36] [37] , derived from BMLF1, BZLF1, and BRLF1
respectively. All epitope peptides will be subsequently abbreviated to the first three amino acids throughout this text. The peptides were purchased from Mimotopes Pty Ltd., Melbourne, Australia and dissolved in 20% dimethyl sulfoxide at 2 mg/ml and diluted in RPMI 1640 to a final concentration of 10μg/ml.
Peptide-specific T-cell cytokine secretion by IFN-γ ELISPOT assay.
The IFN-γ ELISPOT assay has been described in detail elsewhere 26 .
Spots were counted automatically using image analysis software (ImagePro) and were expressed as spot-forming cells (SFC) per 10 6 PBMCs. The number of IFN-γ secreting T-cells was calculated by subtracting the negative control value from the SFC count. 
Flow cytometry
In vitro exposure of PBMC to cell line supernatants
To determine the effect of exposure of PBMC to HL cell line supernatants, 2 x 10 6 PBMC were incubated in either serum-free culture media (SFCM) or supernatants from HRS cell lines (L1236, HDLM2, L428, L540 [38] [39] [40] ).
These cell lines had been previously cultured in SFCM. In some experiments, CD4+ and LAG-3+ T-cells were depleted from these PBMC. This depletion was carried out using a MoFlo high performance cell sorter (DakoCytomation, Carpinteria, CA). Prior to cell sorting, PBMC were stained with PE-labelled anti-CD4 and FITC-labelled anti-LAG-3 antibodies. After incubation, these cells were analysed for CTLA-4 expression and ELISPOT assays as described above.
Statistics
Comparison of patient gender and age between groups was performed using the non-paired T test. For ex vivo studies using IFN-γ ELISPOT, flow cytometry, and peptide-HLA class I pentamers, the Mann Whitney non-parametric test for patients with histologically confirmed HL (Table 1) were stained for LAG-3.
Patients were chosen solely on the basis of availability of tissue. There were no significant differences in age, gender or EBV tissue status between this subgroup and the total group of patients: mean 32 years (subgroup) versus 32 years (total); 40% females versus 38%; and 37% EBV-positive HL versus 37%
respectively. LAG-3 staining on tumor-infiltrating lymphocytes was both at the cell surface and cytoplasmic. LAG-3 predominately stained lymphocytes present in those areas that were rich in HRS cells (see Figure. 1A ). For each tissue section, the mean percentage of LAG-3 expressing cells as a proportion of all cells was calculated from five representative areas visualized using a 40x
objective. Results were then graded in a semi-quantitative manner as a percentage of non-HRS cells within these areas that were positive for LAG-3. A summary of this analysis is presented in Table 2 . Intra-tumoral LAG-3 staining was observed in classical and nodular lymphocyte predominant HL. We also noticed an association between LAG-3 expression and HL histology. In the next set of analyses we compared the frequency of different Treg cell subsets in the peripheral blood from patients with ND/RL HL and those in long-term remission. A summary of this analysis is presented in Figure 3 . The most striking observation was that all different subsets of Treg cells expressing conventional markers or CD4+ LAG-3+ T-cells were consistently elevated in patients with ND/RL HL when compared to the PBMC from patients in long-term remission and to 11 randomly selected healthy laboratory subjects (gender 7F:4M, mean age 37 years, range 22-47). Taken together these data strongly suggest that during active HL there is a significant expansion of Treg cells both at the tumor site and as well in the peripheral blood. Based on these observations, we hypothesized that this expansion may significantly impair antigen-specific T-cell responses.
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Ex-vivo Latent Membrane Protein epitope-specific T-cell functional responses are impaired at diagnosis in HL patients.
To explore the potential effect of Treg cells on the antigen-specific CD8+ memory T-cell response, we longitudinally monitored EBV-specific T-cell responses in a large cohort of HL patients and healthy virus-carriers using interferon-γ (IFN-γ) ELISPOT and MHC-peptide pentamer assays. These cohorts included 94 HL patients (newly diagnosed/ relapsed and long-term remission, Table 1 ) and 29 healthy virus-carriers. For ELISPOT assays, we used a panel of HLA class I restricted CD8+ T-cell epitopes derived from either latent (LMP1/2, EBNA3/4/6) and lytic (BZLF1 and BMLF1) proteins. The detailed data from these ELISPOT analyses is presented in Table 3 and Figure   4 , Panel A-D). Table 3 Unsurprisingly, similar results were seen in patients with active disease irrespective of whether they were newly diagnosed or relapsed (data not shown).
Ex-vivo enumeration of EBV-specific CD8+ T-cells from HL patients shows no difference between active disease and remission.
To determine whether the loss of LMP1 and LMP2 T-cell function was due to the deletion of T-cell precursors, we enumerated antigen-specific T-cells in patients with HL using MHC-peptide pentamers. A summary of this analysis based on a cohort of patients with ND/RL HL, in long-term remission and healthy virus-carriers is presented in Figure 5 . In contrast to the ELISPOT assays, HL patients with acute disease showed normal precursor frequencies of CD8+ T-cells specific for LMP1/2 epitopes when compared to patients in long- Figure 7C ). To determine whether this effect is in part mediated by CD4+ LAG-3+ T-cells, we depleted CD4+ LAG-3+ T-cells from fresh PBMC and from the enriched CD4+ LAG-3+ T-cell population that had been generated following incubation with HRS supernatant PBMC. Purity of FACS sorted cells ranged between 98% and 100%. As can be seen in Figure   7D , removal of CD4+ LAG-3+ T-cells resulted in enhancement of LMP2-specific IFN-γ responses to LMP2 peptides. IFN-γ ELISPOT assays were performed on PBMC from HL patients.
Although this analysis was restricted to those patients with informative alleles, we minimized this limitation by using 29 different EBV peptides presented by a wide-array of MHC class I restricted alleles, such that 97% of our patient population had at least one informative allele (with a median of seven informative HLA class I EBV-specific peptides per patient). An alternate approach would be to use pooled peptides spanning each individual EBV latent protein, thus enabling us to determine effector T-cell function irrespective of HLA restriction 44 . Indeed, this methodology was used to map many of the LMP1/2 peptides used in this study 26 .
In line with our observation of elevated Treg cells prior to therapy, we also noted a selective impairment of LMP1/2-specific effector T-cell function in newly diagnosed or relapsed HL patients when compared to patients in remission and healthy EBV-seropositive individuals. In striking contrast, responses to the immunodominant EBNA3/4/6 and lytic proteins (which are not For *Hasenclever/Diehl International Prognostic Score **Histology available in all Newly Diagnosed and Relapsed cases, and 36 of 43 (84%) remission cases. ***Serology undetermined in one newly diagnosed case. ****Biopsy available for EBV testing in all Newly Diagnosed and Relapsed cases, and 27 of 43 (63%) remission cases. EBV tissue status correlated with histology, with 55% of mixed cellularity or lymphocyte rich cases positive for EBV, against 27% of nodular sclerosing cases (r=0.38, p=0.0127). In 2/67 cases the LMP1 and EBER stains were discordant (EBER positive / LMP1 negative). Both cases were classified as EBV tissue positive.
+/-respectively indicates % of non-HRS cells within HRS rich areas that are positive for LAG-3. ++++ indicates 100-75%, +++ 74-50%, ++ 49-25%, + 24-10%, -/+ 10-2%, -<1%. ND, RL and Remission indicate newly diagnosed, relapsed and Long-term Remission respectively. NA signifies tissue not available for FOXP3 testing. Histology subtypes are NS (nodular sclerosing), MC (mixed cellularity), LR (lymphocyte rich), LD (lymphocyte depleted) and Nodular Lymphocyte Predominant (NLP). There was a significant association between % LAG-3 staining and MC and/or LR histology versus NS (p=0.013) and between LAG3 and positive EBV status (p=0.023). There was no association between % FOXP3 and histology (p=0.489), with EBV status (p=0.833), or with % LAG-3 (p=0.404). % LAG-3 staining in tumor-infiltrating lymphocytes was higher than for % FOXP3 (p=0.003). (8) 87 (24) 101 (25) 153 (33) 102 (40) 221 (77) (8) 87 (24) 101 (25) 153 (33) 102 (40) 221 (77) For personal use only. on January 28, 2018. by guest www.bloodjournal.org From
